1
|
Yang C, Zhu C, Li Y, Li Z, Zhang Z, Xu J, Chen M, Li R, Liu S, Wu Y, Huang Z, Wu C. Injectable selenium-containing polymeric hydrogel formulation for effective treatment of myocardial infarction. Front Bioeng Biotechnol 2022; 10:912562. [PMID: 36032710 PMCID: PMC9403312 DOI: 10.3389/fbioe.2022.912562] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 07/08/2022] [Indexed: 12/04/2022] Open
Abstract
Myocardial infarction (MI) is a serious threat to people’s life and health, which is significantly hindered by effective treatment formulations. Interestingly, our recent endeavour of designing selenium-containing polymeric hydrogel has been experimentally proved to be helpful in combating inflammatory responses and treating MI. The design was inspired by selenium with anti-inflammatory and anti-fibrosis activities, and the formulation could also serve as a support of myocardial tissue upon the failure of this function. In details, an injectable selenium-containing polymeric hydrogel, namely, poly[di-(1-hydroxylyndecyl) selenide/polypropylene glycol/polyethylene glycol urethane] [poly(DH-SE/PEG/PPG urethane)], was synthesised by combining a thermosensitive PPG block, DH-Se (which has oxidation-reduction properties), and hydrophilic PEG segments. Based on the established mouse model of MI, this formulation was experimentally validated to effectively promote the recovery of cardiac function. At the same time, we confirmed by enzyme-linked immunosorbent assay, Masson staining and Western blotting that this formulation could inhibit inflammation and fibrosis, so as to significantly improve left ventricular remodelling. In summary, a selenium-containing polymeric hydrogel formulation analysed in the current study could be a promising therapeutic formulation, which can provide new strategies towards the effective treatment of myocardial infarction or even other inflammatory diseases.
Collapse
Affiliation(s)
- Cui Yang
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Chunyan Zhu
- Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China
| | - Yanling Li
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Zibiao Li
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology, and Research (ASTAR), Singapore, Singapore.,Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), Agency for Science, Technology, and Research (ASTAR), Singapore, Singapore
| | - Zhenghao Zhang
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Jiajia Xu
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Minwei Chen
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Runjing Li
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Shixiao Liu
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Yunlong Wu
- Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China
| | - Zhengrong Huang
- Xiamen Key Laboratory of Cardiac Electrophysiology, Department of Cardiology, School of Medicine, Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China
| | - Caisheng Wu
- Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China
| |
Collapse
|